Aducanumab (Aduhelm) just got FDA approval in dementia, but many experts think it should not have passed the finish line. We interviewed Peter Whitehouse, professor of neurology at Case Western Reserve University and author of American Dementia, on what went wrong.

CME: Clinicians enrolled in our Podcast CME Subscription can access the post-test here.

Published On: 11/15/2021

Duration: 12 minutes, 4 seconds

Referenced Article: “In the News: Aducanumab (Aduhelm),” The Carlat Psychiatry Report, November/December 2021

Chris Aiken, MD, Kellie Newsome, PMHNP, and Peter J. Whitehouse, MD, PhD, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.